Starbucks names Laxman Narasimhan as new CEO, starting in April

Starbucks names Laxman Narasimhan as new CEO, starting in April


Starbucks' new CEO Laxman Narasimhan takes helm in April 2023

Starbucks on Thursday named Laxman Narasimhan as its next chief executive officer.

Narasimhan most recently served as CEO of health and hygiene company Reckitt, which owns brands such as Lysol, Durex and Mucinex. He announced earlier Thursday he was stepping down from that role. He’ll join Starbucks in October, learning about the company and its reinvention plan, before assuming the top job in April.

related investing news

New Starbucks CEO has exactly the kind of consumer experience the coffee chain needs

CNBC Investing Club
New Starbucks CEO has exactly the kind of consumer experience the coffee chain needs

Until then, Howard Schultz will continue as interim CEO of the coffee chain he grew into a global giant. Schultz will remain on Starbucks’ board after Narasimhan succeeds him.

Schultz has been at the helm since April, when his handpicked successor Kevin Johnson retired after five years on the job. Schultz returned to the company as its interim CEO, earning just $1 for his salary. In the meantime, Schultz and the Starbucks board hunted for a long-term successor, with the intention of announcing the new CEO in the fall. (The coffee chain brought back the Pumpkin Spice Latte and other fall menu items on Tuesday.)

Schultz has previously said that he wants to reinvent the employee, customer and store experience to reckon with how the world has changed since the pandemic. The company is holding an investor day on Sept. 13 in Seattle, where it’s expected to unveil more details about the bold changes it plans to make.

Starbucks said in a news release that Schultz will remain “closely involved” with the plan and act as an advisor to Narasimhan.

Narasimhan previously worked at PepsiCo, serving as its global chief commercial officer among other roles. Prior to working at the food and beverage giant, he was a senior partner at McKinsey.

As CEO, he’ll have to tackle a number of challenges. In its home market, Starbucks is facing a union push, with more than 200 stores in the U.S. voting to organize under Workers United. The battle has resulted in negative headlines and legal battles. Inflation hasn’t hurt sales yet, but it has pushed menu prices higher. And China, its second-largest market, is struggling to bounce back from the pandemic, hampered by the country’s zero Covid policy.

“His deep, hands-on experience driving strategic transformations at global consumer-facing businesses makes him the ideal choice to accelerate Starbucks growth and capture the opportunities ahead of us,” Starbucks board chair Mellody Hobson said in a statement.



Source

The  million Trump Card faces legal challenges, limited market
Business

The $5 million Trump Card faces legal challenges, limited market

U.S. President Donald Trump holds “The Trump Card” as he speaks with journalists onboard Air Force One en route to Miami, Florida, U.S., April 3, 2025. Kent Nishimura | Reuters A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to […]

Read More
Nike will report earnings after the bell. Here’s what Wall Street expects
Business

Nike will report earnings after the bell. Here’s what Wall Street expects

A shopper walks past a Nike store, as global markets brace for a hit to trade and growth caused by U.S. President Donald Trump’s decision to impose import tariffs on dozens of countries, in the King of Prussia Mall in King of Prussia, Pennsylvania, U.S., April 3, 2025.  Rachel Wisniewski | Reuters Nike is expected […]

Read More
RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants
Business

RFK Jr.’s CDC vaccine panel backs Merck RSV shot for infants

Nikos Pekiaridis | Nurphoto | Getty Images Robert F. Kennedy Jr.’s revamped government panel of outside vaccine advisors on Thursday recommended the use of Merck‘s shot to protect infants from respiratory syncytial virus, a temporary reprieve for public health officials and companies concerned about the Health and Human Services secretary’s immunization policy. The group, called […]

Read More